A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis (NCT07112378)
🩺 Plain-English Summary (8th-Grade Level)
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and effective the study drug is when given for 24 weeks to children with active EoE. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Who can join: Review the eligibility criteria below.
Location: Phoenix Childrens Hospital — Phoenix, Arizona
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Phoenix Childrens Hospital — Phoenix, Arizona
- University of California San Francisco (UCSF) — San Francisco, California
- Children's Hospital Colorado — Aurora, Colorado
- GI Care for Kids LLC — Atlanta, Georgia
- Massachusetts General Hospital — Boston, Massachusetts
- Weill Cornell Medicine — New York, New York
- University of North Carolina, Bioinformatics Building — Chapel Hill, North Carolina
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- Cook Children's Medical Center — Fort Worth, Texas
- University of Virginia — Charlottesville, Virginia
- Seattle Children's Hospital — Seattle, Washington
- Medical College of Wisconsin, Children's Hospital of Wisconsin — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.